Sporal en es it fr

Sporal Brand names, Sporal Analogs

Sporal Brand Names Mixture

  • No information avaliable

Sporal Chemical_Formula


Sporal RX_link


Sporal fda sheet

Sporal FDA

Sporal msds (material safety sheet)

Sporal MSDS

Sporal Synthesis Reference

No information avaliable

Sporal Molecular Weight

705.633 g/mol

Sporal Melting Point

166.2 oC

Sporal H2O Solubility


Sporal State


Sporal LogP


Sporal Dosage Forms

Capsules (100 mg); Liquid solution

Sporal Indication

For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

Sporal Pharmacology

Itraconazole is an imidazole/triazole type antifungal agent. Itraconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 α-demethylation via the inhibition of the enzyme cytochrome P450 14α-demethylase. This enzyme converts lanosterol to ergosterol, and is required in fungal cell wall synthesis. The subsequent loss of normal sterols correlates with the accumulation of 14 α-methyl sterols in fungi and may be partly responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Itraconazole exhibits in vitro activity against Cryptococcus neoformans and Candida spp. Fungistatic activity has also been demonstrated in normal and immunocompromised animal models for systemic and intracranial fungal infections due to Cryptococcus neoformans and for systemic infections due to Candida albicans.

Sporal Absorption

The absolute oral bioavailability of itraconazole is 55%, and is maximal when taken with a full meal.

Sporal side effects and Toxicity

No significant lethality was observed when itraconazole was administered orally to mice and rats at dosage levels of 320 mg/kg or to dogs at 200 mg/kg.

Sporal Patient Information

No information avaliable

Sporal Organisms Affected

Fungi, yeast and protozoans